Evidence map›Paper›PMID 37679628›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

Targeting Intracellular Antigens with pMHC-Binding Antibodies: A Phage Display Approach.

Zhiyuan Yang, Zhihao Wu, Brian H Santich, Jingbao Liu, Cheng Liu, Nai-Kong V Cheung

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zhiyuan YangEureka Therapeutics, Emeryville, CA, USA.
Zhihao WuDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Brian H SantichGerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Jingbao LiuEureka Therapeutics, Emeryville, CA, USA.
Cheng LiuEureka Therapeutics, Emeryville, CA, USA.
Nai-Kong V CheungDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. cheungn@MSKCC.ORG.
Eureka Therapeutics (United States) · USMemorial Sloan Kettering Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibodies that bind peptide-MHC (pMHC) complex in a manner akin to T cell receptor (TCR) have not only helped in understanding the mechanism of TCR-pMHC interactions in the context of T cell biology but also spurred considerable interest in recent years as potential cancer therapeutics. Traditional methods to generate such antibodies using hybridoma and B cell sorting technologies are sometimes inadequate, possibly due to the small contribution of peptide to the overall B cell epitope space on the surface of the pMHC complex (typical peptide MW = 1 kDa versus MHC MW = 45 kDa) and to the multiple efficiency limiting steps inherent in these methods. In this chapter we describe phage display approaches, including a cell panning strategy, for the rapid generation of such antibodies with high specificity and affinity.

Indexed as

AntibodiesBacteriophagesB-LymphocytesCell MovementCell Surface Display TechniquesHistocompatibility AntigensAntibodiesHistocompatibility AntigensAntibodyFc-fusion proteinHuman leukocyte antigenMajor histocompatibility complexPeptide MHCPhagePhage displayProtein expressionscFvSingle-chain variable fragmentT-cell receptor

Identifiers

PMID37679628
OpenAlexW4386494375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.